D‐512, a novel dopamine D(2/3) receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats

BACKGROUND AND PURPOSE: Symptoms of Parkinson's disease are commonly managed using selective dopamine D(2/3) receptor agonists, including ropinirole. While D(2/3) agonists are useful in early‐stage Parkinson's disease, they tend to lose efficacy in later disease stages and do not appear to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Lindenbach, David, Das, Banibrata, Conti, Melissa M, Meadows, Samantha M, Dutta, Aloke K, Bishop, Christopher
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573415/
https://ncbi.nlm.nih.gov/pubmed/28667675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13937
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados